Phaseline

Companies › Clinique Ovo

Clinique Ovo: clinical trials, targets and expected readouts

2 active drug programs in 4 registered trials: 3 Phase 2, 1 Phase 3; Genitourinary; next expected readout Aug 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Follitropin Delta
Follicle stimulating hormone receptor agonist
FSHRPhase 2IVF; Low Ovarian Reserve; InfertilityAug 2027
HP-hMG (MENOPUR)
Highly purified human menopausal gonadotrophin containing FSH and LH
FSHR, LHCGRPhase 2IVFAug 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07816562Follitropin DeltaPhase 3Low Ovarian ReserveGenitourinaryJul 2027
NCT06997900Follitropin DeltaPhase 2IVFGenitourinaryAug 2027
NCT06997900HP-hMG (MENOPUR)Phase 2IVFGenitourinaryAug 2027
NCT07153367Follitropin DeltaPhase 2InfertilityGenitourinaryDec 2027

Targets

FSHR (2) LHCGR (1)

Companies with the same targets

Qilu Pharmaceutical LG Chem Granata Bio Merck KGaA

Companies built like this

Tioga Pharmaceuticals Azure Biotech Gesynta Pharma Suzhou Sanegene Bio R1 Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.